Wells Fargo & Company Eagle Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 351 shares of EGRX stock, worth $175. This represents 0.0% of its overall portfolio holdings.

Number of Shares

351

Previous 4,007 91.24%

Holding current value

$175

Previous $20,000 95.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$3.34 - $5.6 $12,211 - $20,473	-3,656 Reduced 91.24%	351 $1,000
Q1 2024 May 10, 2024	BUY	$4.26 - $6.51 $3,288 - $5,025	772 Added 23.86%	4,007 $20,000
Q4 2023 Feb 09, 2024	BUY	$4.63 - $15.21 $2,731 - $8,973	590 Added 22.31%	3,235 $16,000
Q3 2023 Nov 13, 2023	SELL	$15.21 - $22.88 $21,050 - $31,665	-1,384 Reduced 34.35%	2,645 $41,000
Q2 2023 Aug 15, 2023	BUY	$17.74 - $31.87 $23,044 - $41,399	1,299 Added 47.58%	4,029 $78,000
Q1 2023 May 12, 2023	BUY	$25.06 - $34.09 $56,284 - $76,566	2,246 Added 464.05%	2,730 $77,000
Q4 2022 Feb 13, 2023	SELL	$24.98 - $39.77 $16,436 - $26,168	-658 Reduced 57.62%	484 $14,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $1,136 - $2,026	43 Added 3.91%	1,142 $31,000
Q2 2022 Aug 12, 2022	SELL	$41.26 - $51.35 $1.69 Million - $2.1 Million	-40,960 Reduced 97.39%	1,099 $48,000
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $88,981 - $104,989	-1,996 Reduced 4.53%	42,059 $2.08 Million
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $10.1 Million - $12.5 Million	-219,766 Reduced 83.3%	44,055 $2.24 Million
Q3 2021 Nov 15, 2021	BUY	$43.79 - $55.78 $3.94 Million - $5.02 Million	90,056 Added 51.83%	263,821 $14.7 Million
Q2 2021 Aug 16, 2021	BUY	$36.86 - $44.5 $4.44 Million - $5.36 Million	120,473 Added 226.06%	173,765 $7.44 Million
Q1 2021 May 13, 2021	BUY	$40.32 - $50.97 $322,439 - $407,607	7,997 Added 17.66%	53,292 $2.22 Million
Q4 2020 Feb 09, 2021	BUY	$41.72 - $51.34 $470,017 - $578,396	11,266 Added 33.11%	45,295 $2.11 Million
Q3 2020 Nov 05, 2020	BUY	$37.02 - $51.28 $11,772 - $16,307	318 Added 0.94%	34,029 $1.45 Million
Q2 2020 Aug 13, 2020	BUY	$43.24 - $55.02 $68,621 - $87,316	1,587 Added 4.94%	33,711 $1.62 Million
Q1 2020 May 14, 2020	BUY	$34.37 - $60.07 $1.1 Million - $1.93 Million	32,124 New	32,124 $1.48 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

9.73M

Call Options Held

1.01M

Put Options Held

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $6.51M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Eagle Pharmaceuticals, Inc. Transaction History